Steen joined Essential Pharma as CEO in May 2021, bringing over 20 years of experience in the speciality pharma and generics sector, across international commercial operations. Early on with Actavis (now Teva) he grew their EMEA business via acquisitions and organic growth. After a stint in biotech with vaccines developer Bavarian Nordic, he joined Mylan (now Viatris). A critical deliverable was the successful transfer and integration of Abbott's generic division in Europe. ($1.7bn turnover, 113SKUs across 36 markets). Subsequently Steen moved into private equity funded ventures. Prior to Essential Pharma he was with Covis Pharma establishing and running their global business ex-US.
He is based in Switzerland. His education background is in Sports Sciences and he holds a MBA from London Business School.
Colin joined Essential Pharma in December 2020 as Chief Operating Officer, where he is operationally responsible for regulatory affairs, medical affairs, pharmacovigilance and quality assurance.
He has more than 35 years of uninterrupted experience in medicines, within the pharmaceutical, contract research and consumer healthcare sectors, having also worked for Syntex Pharmaceuticals, Quintiles and Mentholatum respectively. He has enjoyed roles in pharmaceutical development, clinical supplies manufacturing, technology transfer, commercial production, quality compliance and project management.
Colin graduated with a BSc (Hons) in Applied Chemistry from Napier University in Edinburgh and is a Chartered Chemist, a Chartered Scientist and a Fellow of The Royal Society of Chemistry.
Ben joined Essential Pharma in April 2020 bringing a wealth of global financial experience. He has held a number of finance leadership positions over the last 10 years in the pharmaceutical industry - most recently at PTC Therapeutics (a US-listed biotech) and Shire . Prior to his tenure in pharma, he had roles of increasing importance across a number of different industry sectors.
Ben is a member of the Institute of Chartered Accounts in England and Wales.
Andy joined Essential Pharma as General Counsel in January 2022. He has worked across Europe and in the US during a legal career spanning more than 15 years. Before joining Essential Pharma, Andy was UK&I General Counsel and in charge of Legal Transactions for EMENA at Accord Healthcare (the largest supplier of generic medicines to the UK’s NHS) for more than 3 years. Prior to that, Andy worked in the corporate department at the law firm Linklaters for over 11 years, where he was involved in multiple transactions in the pharma sector, including during 2 years working in New York and more than 9 months on secondment with Novartis in Switzerland.
Andy graduated with a BA in Law from the University of Oxford and is a Solicitor of the Senior Courts of England and Wales.
Soren has close to 15 years of global biopharmaceutical experience in both commercial and business development. He joined Essential Pharma in June 2022 from Porton BioPharma where, as a Director, he had responsibility for establishing new strategic collaborations and overseeing the development and manufacturing of various therapeutic products. Prior to this, Soren worked at Mitsubishi Tanabe Pharma Corporation in Business Development where he was responsible for driving major growth opportunities and the successful execution of in-licence agreements.
Soren graduated from the University of Cambridge.
Ingvild joined Essential Pharma in 2010, she started in regulatory and pharmacovigilance, before moving on to business development and management.
She has experience in managing manufacturing site transfers, product development and clinical trials (as a sponsor) and has led the integration of all Essential Pharma’s acquisitions since 2014.
Ingvild has a Cand.Pharm degree (M.Pharm) from the University of Oslo, and before joining Essential she worked in the retail and hospital pharmacy sector for 8 years.
Fabio comes to us with over 20 years of experience in the pharmaceutical supply chain function. Having spent the past seven years at Teva Pharmaceuticals Fabio was initially bought into the company to establish the Global Hub for Specialties and Branded Generics, which then evolved in the Global Hub for Specialities and Biosimilar / Biologicals.
He has lived and worked in Italy, Hungary and Switzerland with frequent travel to the US and across Europe for Corporate companies like ExxonMobil, General Electric, Nxp, Varian covering different roles in Supply Chain
He holds a MSc in Procurement, Supply Chain and Logistic from the University of Salford (UK) and became a Member of CIPS in 2022.
Georgy joined Essential Pharma as HR Director in June 2021, bringing over 21 years of experience in people and talent across a variety of industries including Medical Devices, Pharmaceuticals and Financial News and Data. Georgy has experience offering HR advisory services from across the EMEA Region. Starting her career in contingency recruitment across disciplines and regions Georgy transitioned to HR whilst at Bloomberg where she worked with the News division providing HR Business Partnering across EMEA before moving on to Bausch + Lomb, where she developed her HR career supporting Surgical, Pharmaceutical and Vison care consumer health.
Her education background is in Sociology & Psychology and she is Chartered Member of the CIPD.
Laura Castagno was appointed Senior Director of QA, RA and PV in Switzerland in March 2022, assuming direct responsibility for the global regulatory team shortly thereafter. She has since assumed the duties of the Responsible Person for Essential Pharma in Switzerland. She has over 25 years’ experience in the pharmaceutical industry and joined from Corza Medical, a global manufacturer of innovative surgical technologies, where she worked as the Director of Pharmacovigilance, Regulatory, Quality and Medical Information. Prior to that, Laura was the Director of Global Regulatory Affairs and Quality at Primex Pharmaceuticals where she managed quality and regulatory activities for medicinal products registered in more than 50 countries worldwide. In this position she was also the Responsible Person for distribution and PV activities in Switzerland.
Laura graduated with an MSc in Chemistry and Pharmaceutical Technology from the University of Turin (Italy) and has a Masters in Patents and Intellectual Property from the University of Milan (Italy).
Corrine joined Essential Pharma in November 2012 with several years’ experience in drug regulatory affairs. She has enjoyed a varied role in the organisation working primarily in regulatory affairs, working closely with contract manufacturers on technical and quality projects. She has played a key role in technical transfers and has been part of the integration team for many products across several markets. Her role has also included oversight of pharmacovigilance and medical information functions in more recent years.
Corrine graduated from the University of Bath with a degree in pharmacy and a PhD in medicinal chemistry. She is a qualified pharmacist with over 18 years of experience in the pharmaceutical industry, working in pharmaceutical development, clinical trials and regulatory affairs.
Nour joined in May 2021 as Responsible Person, Responsible Person (import) and Director QA. Before joining Essential Pharma, she was the head of Quality & Lead Responsible Person. She is a pharmacist by training with a Masters degree and is a member of the General Pharmaceutical Council and Royal Pharmaceutical Society.
Having worked among wider sectors including hospital and community pharmacies, and with 11 years in the pharmaceutical industry, Nour brings vast experience in the quality field.
Joanne leads and manages the in-house compliance function at Essential Pharma, and has accountability in the areas of corporate governance, risk and compliance.
She has a background in Pharmacy, Law and Compliance, and is a UK registered industrial pharmacist.
Annabelle joined Essential Pharma in January 2021, bringing over 14 years of experience in mergers and acquisitions across various sectors in the Healthcare space.
Prior to joining Essential Pharma, Annabelle worked in boutique transactions advisory firms and was a Director at Results Healthcare, and a Vice President at Torreya Partners. She worked in the Healthcare team at Merill Lynch prior to these.
In these roles, Annabelle was responsible for the acquisition and divestment of multiple products and portfolios. She led the project team for the divestment of UCB’s alprostadil product, and was involved the SpePharm JV with Norgine, and Kyowa Hakko Kirin’s acquisition of Prostrakan.
Annabelle has a BSc in Economics from UCL.